Literature DB >> 33028593

Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.

Hao Xie1, Douglas W Mahoney2, Patrick H Foote3, Kelli N Burger2, Karen A Doering3, William R Taylor3, Sara S Then3, Xiaoming Cao3, Maria McGlinch3, Calise K Berger3, Tsung-Teh Wu4, Joleen M Hubbard1, Hatim T Allawi5, Michael W Kaiser5, Graham P Lidgard5, David A Ahlquist3, John B Kisiel6.   

Abstract

PURPOSE: We aimed to assess the concordance of colorectal cancer-associated methylated DNA markers (MDM) in primary and metastatic colorectal cancer for feasibility in detection of distantly recurrent/metastatic colorectal cancer in plasma. EXPERIMENTAL
DESIGN: A panel of previously discovered colorectal cancer-associated MDMs was selected. MDMs from primary and paired metastatic colorectal cancer tissue were assayed with quantitative methylation-specific PCR. Plasma MDMs were measured blindly by target enrichment long-probe quantitative-amplified signal assays. Random forest modeling was used to derive a prediction algorithm of MDMs in archival plasma samples from primary colorectal cancer cases. This algorithm was validated in prospectively collected plasma samples from recurrent colorectal cancer cases. The accuracy of the algorithm was summarized as sensitivity, specificity, and area under the curve (AUC).
RESULTS: Of the 14 selected MDMs, the concordance between primary and metastatic tissue was considered moderate or higher for 12 MDMs (86%). At a preset specificity of 95% (91%-98%), a panel of 13 MDMs, in plasma from 97 colorectal cancer cases and 200 controls, detected stage IV colorectal cancer with 100% (80%-100%) sensitivity and all stages of colorectal cancer with an AUC of 0.91 (0.87-0.95), significantly higher than carcinoembryonic antigen [AUC, 0.72 (0.65-0.79)]. This panel, in plasma from 40 cases and 60 healthy controls, detected recurrent/metastatic colorectal cancer with 90% (76%-97%) sensitivity, 90% (79%-96%) specificity, and an AUC of 0.96 (0.92-1.00). The panel was positive in 0.30 (0.19-0.43) of 60 patients with no evidence of disease in post-operative patients with colorectal cancer.
CONCLUSIONS: Plasma assay of novel colorectal cancer-associated MDMs can reliably detect both primary colorectal cancer and distantly recurrent colorectal cancer with promising accuracy. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33028593      PMCID: PMC7785570          DOI: 10.1158/1078-0432.CCR-20-2589

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  26 in total

1.  Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

Authors:  Thierry André; Dewi Vernerey; Laurent Mineur; Jaafar Bennouna; Jérôme Desrame; Roger Faroux; Serge Fratte; Marine Hug de Larauze; Sophie Paget-Bailly; Benoist Chibaudel; Jeremie Bez; Jérôme Dauba; Christophe Louvet; Céline Lepere; Olivier Dupuis; Yves Becouarn; May Mabro; Joëlle Egreteau; Olivier Bouche; Gaël Deplanque; Marc Ychou; Marie Pierre Galais; François Ghiringhelli; Louis Marie Dourthe; Jean-Baptiste Bachet; Ahmed Khalil; Franck Bonnetain; Aimery de Gramont; Julien Taieb
Journal:  J Clin Oncol       Date:  2018-04-05       Impact factor: 44.544

2.  Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection.

Authors:  Alexander M Aravanis; Mark Lee; Richard D Klausner
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.

Authors:  Thomas Reinert; Lone V Schøler; Rune Thomsen; Heidi Tobiasen; Søren Vang; Iver Nordentoft; Philippe Lamy; Anne-Sofie Kannerup; Frank V Mortensen; Katrine Stribolt; Stephen Hamilton-Dutoit; Hans J Nielsen; Søren Laurberg; Niels Pallisgaard; Jakob S Pedersen; Torben F Ørntoft; Claus L Andersen
Journal:  Gut       Date:  2015-02-04       Impact factor: 23.059

4.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 5.  Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer.

Authors:  Emile Tan; Nikos Gouvas; R John Nicholls; Paul Ziprin; Evaghelos Xynos; Paris P Tekkis
Journal:  Surg Oncol       Date:  2008-07-10       Impact factor: 3.279

6.  Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.

Authors:  John B Kisiel; Brian A Dukek; Reddappa V S R Kanipakam; Hassan M Ghoz; Tracy C Yab; Calise K Berger; William R Taylor; Patrick H Foote; Nasra H Giama; Kristeen Onyirioha; Mohamed A Abdallah; Kelli N Burger; Seth W Slettedahl; Douglas W Mahoney; Thomas C Smyrk; Jason T Lewis; Maria Giakoumopoulos; Hatim T Allawi; Graham P Lidgard; Lewis R Roberts; David A Ahlquist
Journal:  Hepatology       Date:  2019-02-05       Impact factor: 17.425

Review 7.  Screening of colorectal cancer: present and future.

Authors:  Marcello Maida; Fabio Salvatore Macaluso; Gianluca Ianiro; Francesca Mangiola; Emanuele Sinagra; Georgina Hold; Carlo Maida; Giovanni Cammarota; Antonio Gasbarrini; Giuseppe Scarpulla
Journal:  Expert Rev Anticancer Ther       Date:  2017-10-26       Impact factor: 4.512

8.  Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.

Authors:  Jeanne Tie; Joshua D Cohen; Yuxuan Wang; Michael Christie; Koen Simons; Margaret Lee; Rachel Wong; Suzanne Kosmider; Sumitra Ananda; Joseph McKendrick; Belinda Lee; Jin Hee Cho; Ian Faragher; Ian T Jones; Janine Ptak; Mary J Schaeffer; Natalie Silliman; Lisa Dobbyn; Lu Li; Cristian Tomasetti; Nicholas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs
Journal:  JAMA Oncol       Date:  2019-12-01       Impact factor: 31.777

9.  A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer.

Authors:  Graeme P Young; Susanne K Pedersen; Scott Mansfield; David H Murray; Rohan T Baker; Philippa Rabbitt; Susan Byrne; Libby Bambacas; Paul Hollington; Erin L Symonds
Journal:  Cancer Med       Date:  2016-10-11       Impact factor: 4.452

10.  Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.

Authors:  John N Primrose; Rafael Perera; Alastair Gray; Peter Rose; Alice Fuller; Andrea Corkhill; Steve George; David Mant
Journal:  JAMA       Date:  2014-01-15       Impact factor: 56.272

View more
  7 in total

1.  Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.

Authors:  Lisa M Marinelli; John B Kisiel; Seth W Slettedahl; Douglas W Mahoney; Maureen A Lemens; Vijayalakshmi Shridhar; William R Taylor; Julie K Staub; Xiaoming Cao; Patrick H Foote; Kelli N Burger; Calise K Berger; Maria C O'Connell; Karen A Doering; Maria Giakoumopoulos; Hannah Berg; Carla Volkmann; Adam Solsrud; Hatim T Allawi; Michael Kaiser; Abram M Vaccaro; Catherine Albright Crawford; Cynthia Moehlenkamp; Gracie Shea; Melissa S Deist; J Kenneth Schoolmeester; Sarah E Kerr; Mark E Sherman; Jamie N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2022-03-31       Impact factor: 5.304

Review 2.  Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.

Authors:  Farah J Nassar; Zahraa S Msheik; Rihab R Nasr; Sally N Temraz
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

3.  LINC01116 facilitates colorectal cancer cell proliferation and angiogenesis through targeting EZH2-regulated TPM1.

Authors:  Weijie Liang; Jie Wu; Xinguang Qiu
Journal:  J Transl Med       Date:  2021-01-26       Impact factor: 5.531

4.  Using Comorbidity Pattern Analysis to Detect Reliable Methylated Genes in Colorectal Cancer Verified by Stool DNA Test.

Authors:  Yi-Chiao Cheng; Po-Hsien Wu; Yen-Ju Chen; Cing-Han Yang; Jhen-Li Huang; Yu-Ching Chou; Pi-Kai Chang; Chia-Cheng Wen; Shu-Wen Jao; Hsin-Hui Huang; Yi-Hsuan Tsai; Tun-Wen Pai
Journal:  Genes (Basel)       Date:  2021-09-28       Impact factor: 4.096

Review 5.  The role of epigenetic modifications in Colorectal Cancer Metastasis.

Authors:  Riya Su; Xinlin Wu; Liang Tao; Changshan Wang
Journal:  Clin Exp Metastasis       Date:  2022-04-16       Impact factor: 4.510

Review 6.  Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).

Authors:  Sakti Chakrabarti; Anup Kumar Kasi; Aparna R Parikh; Amit Mahipal
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

7.  A meta-analysis of the value of circulating tumor cells in monitoring postoperative recurrence and metastasis of colorectal cancer.

Authors:  Jiao Wu; Zhongyu Li; Jianhua Zou; Liusheng Li; Ning Cui; Tengteng Hao; Kangjun Yi; Jingyan Yang; Yu Wu
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.